Piper Jaffray commented on Hologic HOLX in a report released today. In the report, Piper Jaffray was positive in its assessment of the company.
Piper Jaffray writes, "
FDA released the monthly MQSA National Statistics update, with 9,571 accredited
full field digital mammography (FFDM) systems in place as of June 1, 2011,
representing a 94 system increase for the month. Assuming the April/May average
FFDM placements of 92 hold for June, plus the impact of the early stage
replacement cycle (est. 15%, not captured by MQSA), suggests potential downside
of $3.4M to our 3Q11 Breast Health estimate, although we view mix shift to
higher-end system configurations (i.e. tomo-ready/enabled) represents a potential
offset to weaker-than-expected placements (if current quarter-to-date trends hold).
Overall, our Hologic thesis remains unchanged and we anticipate a benefit from
both the early stage tomosynthesis adoption cycle and improving physician office
visit trend"
Piper Jaffray currently has an Overweight rating on Hologic and a price target of $26. Shares of HOLX closed at $20.82 on Wednesday, down 3.16% from the open.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in